Physician profile
Eric Nelson
NPI 1710983754
$12,773.19
in general payments reported to CMS, 2019-2025
62 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,636 · 2020: $1,397 · 2021: $1,612 · 2022: $2,942 · 2023: $3,328 · 2024: $394 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,086 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,086.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,329.42 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,066.61 | 2019-2024 | Opdivo, Pomalyst |
| Janssen Biotech, INC. | $941.80 | 2019-2023 | Imbruvica, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $707.10 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $541.55 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $534.86 | 2019-2023 | |
| Pfizer INC. | $500.84 | 2019-2023 | |
| Astellas Pharma US INC | $492.47 | 2019-2022 | |
| Amgen INC. | $488.09 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Eisai INC. | $474.20 | 2019-2023 | |
| Seagen INC. | $438.06 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Daiichi Sankyo INC. | $409.43 | 2020-2025 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $390.65 | 2019-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $369.91 | 2019-2023 | Onivyde |
| Incyte Corporation | $368.45 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.